Recursion (RXRX, Financial) is set to unveil initial findings from its ongoing TUPELO clinical trial at the 2025 Digestive Disease Week conference. This Phase 1b/2 trial investigates the safety and early effectiveness of the company's drug candidate, REC-4881, for familial adenomatous polyposis (FAP), a rare genetic disorder linked to colorectal cancer risk.
The presentation, slated as a late-breaking oral session, will occur during the Research Forum on Hereditary GI cancer syndromes on May 4, 2025, in San Diego. The significance of REC-4881 is underscored by the absence of FDA-approved treatments for FAP, which affects approximately 50,000 individuals across the United States and several European countries, including France, Germany, Italy, Spain, and the UK.
REC-4881 has received both Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration and an Orphan Drug designation from the European Commission. These designations are pivotal as they facilitate faster development and review processes, addressing the unmet medical needs of FAP patients.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Recursion Pharmaceuticals Inc (RXRX, Financial) is $8.50 with a high estimate of $11.00 and a low estimate of $6.00. The average target implies an upside of 50.98% from the current price of $5.63. More detailed estimate data can be found on the Recursion Pharmaceuticals Inc (RXRX) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Recursion Pharmaceuticals Inc's (RXRX, Financial) average brokerage recommendation is currently 2.8, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Recursion Pharmaceuticals Inc (RXRX, Financial) in one year is $11.41, suggesting a upside of 102.66% from the current price of $5.63. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Recursion Pharmaceuticals Inc (RXRX) Summary page.
